Clinical Trial

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Name: A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL — clinical trial record (NCT06547528)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-08-07.

Trial Details

NCT Number	NCT06547528
Lead Sponsor	Ono Pharmaceutical Co., Ltd.
Conditions	Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment	108 participants
Start Date	2023-10-01
Primary Completion	2029-01-31 (estimated)
Study Completion	2029-04-30 (estimated)
Updated on ClinicalTrials.gov	2025-06-03